AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

MESOBLAST LTD

1.705

-0.040-2.29%

Volume:3.93M

Turnover:6.74M

Market Cap:2.18B

PE:-11.84

High:1.775

Open:1.750

Low:1.685

Close:1.745

Loading ...

Overview Company News Filings

Mesoblast to Be Added to Nasdaq Biotechnology Index

THOMSON REUTERS

Mesoblast to be Added to Nasdaq Biotechnology Index

MT Newswires Live

Mesoblast Ltd File Prospectus Relates to Offer, Sale From Time to Time by Selling Shareholder of up to 2 Mln Ordinary Shares

THOMSON REUTERS

RFK Jr. could prove a surprise boon for stem-cell stocks with pivotal year ahead

Stem Cells Poised for Success in 2025 as Regulatory Environment Looks More Favorable -- Market Talk

If you'd invested $5,000 in this ASX 300 healthcare stock a year ago, you'd now have $30,000!

Exploring High Growth Tech Stocks in Australia December 2024

Simply Wall St.

ASX Market Update: Energy stocks drag bourse lower

The Market Herald

Why 29Metals, Guzman Y Gomez, Mesoblast, and Pilbara Minerals shares are falling today

Mesoblast Secures Regenerative Advanced Therapy Designation from US FDA for Cellular Therapy Product; Shares Hit Near 3.5-Year High

MT Newswires Live

BRIEF-Mesoblast Says FDA Grants Mesoblast RMAT Designation

What on Earth is happening with Mesoblast shares today?

FDA Grants Revascor® (Rexlemestrocel-L) Regenerative Medicine Advanced Therapy (Rmat) Designation in Children With Congenital Heart Disease

THOMSON REUTERS

Mesoblast Ltd-FDA Grants Mesoblast Rmat Designation

THOMSON REUTERS

Mesoblast's Cell Therapy Shows Improved Outcomes in Heart Disease Patients in Phase 3 Study

MT Newswires Live

Top ASX shares to buy in December 2024

Mesoblast Limited's (ASX:MSB) 17% gain last week benefited both retail investors who own 54% as well as insiders

Simply Wall St.

11 ASX All Ords shares rising faster than Nvidia over the past year

3 ASX 300 stocks up by more than 300% in a year

Up 427% this year, why today is a big day for Mesoblast shares

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/MSB.AU/news?page=8"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MSB.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MSB.AU\",,,,,undefined,":{"symbol":"MSB.AU","market":"AU","secType":"STK","nameCN":"MESOBLAST LTD","latestPrice":1.705,"timestamp":1746771120000,"preClose":1.745,"halted":0,"volume":3929841,"delay":0,"nameEN":"MESOBLAST LTD","floatShares":784305641,"shares":1277239284,"eps":-0.14395849586518955,"marketStatus":"Not Yet Opened","change":-0.04,"latestTime":"05-09 16:12:00 AEST","open":1.75,"high":1.775,"low":1.685,"amount":6738047,"amplitude":0.051576,"askPrice":1.71,"askSize":45000,"bidPrice":1.7,"bidSize":21585,"shortable":3,"etf":0,"ttmEps":-0.14395849586518955,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1747008000000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":1.745,"openAndCloseTimeList":[[1746748800000,1746770400000]],"volumeRatio":0.8128105532208209,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MSB.AU\",,,,,undefined,":{"symbol":"MSB.AU","floatShares":784305641,"roa":"-4.85%","roe":"-21.31%","lyrEps":-0.139087,"volumeRatio":0.8128105532208209,"shares":1277239284,"dividePrice":0,"high":1.775,"amplitude":0.051576,"preClose":1.745,"low":1.685,"week52Low":0.88,"pbRate":"3.03","psRate":"246.15","week52High":3.37,"institutionHeld":0,"latestPrice":1.705,"committee":-0.351656,"eps":-0.14395849586518955,"divideRate":0,"volume":3929841,"delay":0,"ttmEps":-0.14395849586518955,"open":1.75,"prevYearClose":3.1,"prevWeekClose":1.845,"prevMonthClose":1.795,"prevQuarterClose":1.96,"fiveDayClose":1.845,"twentyDayClose":1.75,"sixtyDayClose":2.98},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MSB.AU\",pageSize:20,pageCount:8,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2492900818","title":"Mesoblast to Be Added to Nasdaq Biotechnology Index","url":"https://stock-news.laohu8.com/highlight/detail?id=2492900818","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492900818?lang=en_us&edition=fundamental","pubTime":"2024-12-18 20:30","pubTimestamp":1734525000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241218:nTUA28CKHJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","IE00B64PRP62.GBP","IE00BKPKM429.USD","LU2210149790.SGD","LU2095319765.USD","LU2210150020.SGD","BK4585","NDAQ","BK4588","BK7501","MSB.AU","BK7508","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","BK4112"],"gpt_icon":0},{"id":"2492923107","title":"Mesoblast to be Added to Nasdaq Biotechnology Index","url":"https://stock-news.laohu8.com/highlight/detail?id=2492923107","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492923107?lang=en_us&edition=fundamental","pubTime":"2024-12-18 12:00","pubTimestamp":1734494447,"startTime":"0","endTime":"0","summary":"Mesoblast (ASX:MSB) will be added to the Nasdaq Biotechnology Index, effective after the US markets open on Dec. 23, according to a Wednesday filing with the Australian bourse.The company's shares rose nearly 2% in recent Wednesday trade.Price (AUD): $1.98, Change: $+0.04, Percent Change: +1.91%","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0994945656.USD","MSB.AU","LU2238339852.HKD","IE00B3QW5Z07.USD","MESO","LU2095319765.USD","LU2210150020.SGD","AUD","BK7501",".IXIC","IE00BGHQF748.EUR","BK4588","BK7508","NQmain","XAO.AU","BK4585","BK7067","LU0345774631.USD","IE00BKPKM429.USD","XKO.AU","XJO.AU","BK4112","IE00B64PRP62.GBP","LU2210149790.SGD","BK4125","BK4139","LU0426412945.USD","LU1043141123.HKD","NDAQ","LU0426417589.USD"],"gpt_icon":0},{"id":"2491583524","title":"Mesoblast Ltd File Prospectus Relates to Offer, Sale From Time to Time by Selling Shareholder of up to 2 Mln Ordinary Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2491583524","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491583524?lang=en_us&edition=fundamental","pubTime":"2024-12-14 05:07","pubTimestamp":1734124029,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241213:nFWN3NE0T5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7501","MSB.AU","BK7067"],"gpt_icon":0},{"id":"2491317453","title":"RFK Jr. could prove a surprise boon for stem-cell stocks with pivotal year ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2491317453","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491317453?lang=en_us&edition=fundamental","pubTime":"2024-12-13 01:08","pubTimestamp":1734023280,"startTime":"0","endTime":"0","summary":"Maxim is expecting a breakthrough and names two stocks as beneficiaries. Stem-cell research is on the cusp of a breakthrough that could come as soon as 2025, and two biotech companies with promising therapies stand to gain, according to a new report from Maxim Group on Thursday.Mesoblast Ltd. , a Melbourne, Australia-based company that's seeking to develop cellular medicines for inflammatory diseases, and Capricor Therapeutics Inc. , a San Diego-based biotech developing cell-based treatments for rare diseases, are in the process of applying for Food and Drug Administration approvals that could come next year, according to Maxim analysts Jason McCarthy and Michael Okunewitch.The regenerative stem-cell-based therapy space experienced a boost in the mid-2010s that led to the emergence of a number of biotech companies eager to ride the wave, but the celebrations soon died down as companies faced regulatory setbacks as well as scientific ones, the analysts wrote.A more supportive health dep","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","CAPR","BK7501","BK7508","MSB.AU","MESO","BK4139"],"gpt_icon":1},{"id":"2490438792","title":"Stem Cells Poised for Success in 2025 as Regulatory Environment Looks More Favorable -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2490438792","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490438792?lang=en_us&edition=fundamental","pubTime":"2024-12-12 23:05","pubTimestamp":1734015900,"startTime":"0","endTime":"0","summary":"1005 ET - Regenerative stem cell-based therapies are poised for a breakthrough as the potential for approvals looks set to thrive in a more favorable regulatory environment, says Maxim Group's Jason McCarthy in a research note. The analyst says such therapies came onto the scene in the mid-2010s and contracted shortly afterwards, but can now step back into the limelight. McCarthy notes that two companies that have benefited from recent changes are Mesoblast and Capricor Therapeutics, with valuations of both rising significantly this year. He adds that RFK Jr., Trump's pick to run the Department of Health and Human Services, seems enthusiastic about stem cell research despite criticizing vaccines and fluoride. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAPR","MSB.AU","BK7501","BK7508","BK7067","BK4139","MESO"],"gpt_icon":1},{"id":"2490710819","title":"If you'd invested $5,000 in this ASX 300 healthcare stock a year ago, you'd now have $30,000!","url":"https://stock-news.laohu8.com/highlight/detail?id=2490710819","media":"MotleyFool","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490710819?lang=en_us&edition=fundamental","pubTime":"2024-12-12 06:30","pubTimestamp":1733956200,"startTime":"0","endTime":"0","summary":"Well, it's none other than biotech company Mesoblast Ltd . Yep, one year ago, you could have bought this ASX 300 stock for just 27 cents a pop. Today, those same shares are going for $1.63 each. That means if one had put $5,000 into Mesoblast shares in December of 2023, they would have been able to amass 18,518 shares . Today, those 18,518 shares would have a value of $30,184.34. Not a bad return for just one year of waiting. So, how has this ASX 300 healthcare stock delivered such an eye-watering gain in so little time?How has this ASX 300 healthcare stock rocketed 500% in a year?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/12/12/if-youd-invested-5000-in-this-asx-300-healthcare-stock-a-year-ago-youd-now-have-30000/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7094","BK7135","XRO.AU","BK7508","BK7067","BK7501","BHP.AU","CBA.AU","BK7095","BK7507","BLA.AU","WTC.AU","BK7503","MSB.AU","PME.AU","BK7016","BK7511"],"gpt_icon":0},{"id":"2489592109","title":"Exploring High Growth Tech Stocks in Australia December 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2489592109","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489592109?lang=en_us&edition=fundamental","pubTime":"2024-12-05 12:07","pubTimestamp":1733371641,"startTime":"0","endTime":"0","summary":"As the Australian market experiences a modest uptick with the ASX200 rising by 0.3% to 8,488 points, the IT sector stands out as a strong performer, climbing by 1.1%, amidst broader economic indicators suggesting potential volatility and constraints in the coming year. In this environment, identifying high-growth tech stocks requires careful consideration of their ability to thrive in dynamic conditions and leverage technological advancements to sustain momentum within an evolving market landscape.Click here to see the full list of 58 stocks from our ASX High Growth Tech and AI Stocks screener.Overview: FINEOS Corporation Holdings plc develops and sells enterprise claims and policy management software for the employee benefits and life, accident, and health insurance industries globally, with a market capitalization of A$652.96 million.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exploring-high-growth-tech-stocks-040721351.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["XJO.AU","XKO.AU","BK7067","MSB.AU","BK7508","BK7016","XAO.AU","CUV.AU","MESO","FCL.AU","BK7501"],"gpt_icon":0},{"id":"2489170549","title":"ASX Market Update: Energy stocks drag bourse lower","url":"https://stock-news.laohu8.com/highlight/detail?id=2489170549","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489170549?lang=en_us&edition=fundamental","pubTime":"2024-12-05 10:18","pubTimestamp":1733365080,"startTime":"0","endTime":"0","summary":"The ASX200 has been up 0.3% at 8,488 points.Shane Oliver, Chief Economist at AMP says 2025 is likely to see positive returns, but after the surprising calm of 2024, it’s likely to be far more volatile and more constrained.IT has been the strongest performing sector, up 1.1%, followed by Real Estate, up 0.8% and Discretionary, up 0.75%.Energy has been the biggest loser, down 0.75%, followed by Materials, down 0.4% and Health Care, down 0.2%.Woodside  has been down 0.8% after inking a revised lump sum turnkey engineering, procurement, and construction  contract withBechtelfor the development of Louisiana LNG.Magnetic Resources NL has been down 0.8% on strong gold results from recent metallurgical testing work at its Lady Julie North 4  project in WA.Mesoblasthas been down 8.2% on news theU.S.Food and Drug Administration has granted Regenerative Medicine Advanced Therapy designation for its cellular therapy Revascor .","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/asx-market-update-energy-stocks-drags-bourse-lower-2024-12-05/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["MSB.AU","BK7501","BK4183","MAU.AU","WDS.AU","BK7508","BK7067","EPC","BK7142","BK7095"],"gpt_icon":0},{"id":"2489703211","title":"Why 29Metals, Guzman Y Gomez, Mesoblast, and Pilbara Minerals shares are falling today","url":"https://stock-news.laohu8.com/highlight/detail?id=2489703211","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489703211?lang=en_us&edition=fundamental","pubTime":"2024-12-05 10:02","pubTimestamp":1733364143,"startTime":"0","endTime":"0","summary":"TheS&P/ASX 200 Index (ASX: XJO) is back on from and pushing higher on Thursday afternoon. At the time of writing, the benchmark index is up 0.3% to 8,487.9 points. Four ASX shares that have failed to ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/12/05/why-29metals-guzman-y-gomez-mesoblast-and-pilbara-minerals-shares-are-falling-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["PLS.AU","BK7507","GYG.AU","XJO.AU","LRS.AU","MSB.AU","MTX","BK7504","BK4109","BK7501","MESO","29M.AU","BK7095","BK7137","BK7067","BK7508","BK4139"],"gpt_icon":0},{"id":"2489017966","title":"Mesoblast Secures Regenerative Advanced Therapy Designation from US FDA for Cellular Therapy Product; Shares Hit Near 3.5-Year High","url":"https://stock-news.laohu8.com/highlight/detail?id=2489017966","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489017966?lang=en_us&edition=fundamental","pubTime":"2024-12-05 09:37","pubTimestamp":1733362628,"startTime":"0","endTime":"0","summary":"Mesoblast  secured a regenerative advanced therapy designation from the US Food and Drug Administration for Revascor-branded rexlemestrocel-L cell therapy for pediatric patients with congenital heart disease, according to a Thursday filing with the Australian bourse.The status was granted following results from a clinical trial investigating the use of the therapy in children with hypoplastic left heart syndrome , the filing said.Revascor was previously granted by the health regulator with both a rare pediatric disease designation and an orphan drug designation for pediatric patients with HLHS, the filing added.The company's shares tumbled almost 8% in recent Thursday trade but earlier hit their highest since August 2021.Price : $1.62, Change: $-0.14, Percent Change: -7.95%","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0426412945.USD","BK4157","BK6522","IE00B19Z4B17.USD","LU0345774631.USD","BK4139","LU1043141123.HKD","IE00B66KJ199.SGD","LU0994945656.USD","BK7508","BK7067","MSB.AU","LU2238339852.HKD","IE00B7SZL793.SGD","MESO","IE0031619046.USD","BLZ.SI","BK4125","LU0426417589.USD","AUD","BK6088","AEIS","BK7501"],"gpt_icon":0},{"id":"2489175079","title":"BRIEF-Mesoblast Says FDA Grants Mesoblast RMAT Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=2489175079","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489175079?lang=en_us&edition=fundamental","pubTime":"2024-12-05 09:17","pubTimestamp":1733361444,"startTime":"0","endTime":"0","summary":"Dec 5 (Reuters) - Mesoblast Ltd   :   * FDA GRANTS MESOBLAST RMAT DESIGNATIONFurther company coverage:    ((Reuters.Briefs@thomsonreuters.com;;))","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"BRIEF-Mesoblast Says FDA Grants Mesoblast RMAT Designation","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7067","MSB.AU","BK7508"],"gpt_icon":0},{"id":"2489175834","title":"What on Earth is happening with Mesoblast shares today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2489175834","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489175834?lang=en_us&edition=fundamental","pubTime":"2024-12-05 08:54","pubTimestamp":1733360055,"startTime":"0","endTime":"0","summary":"Investors were buying and then selling the company's shares today after the allogeneic cellular medicines developer made a major announcement. According to the release, the United States Food and Drug Administration  has granted its second generation allogeneic, STRO3-immunoselected, and industrially manufactured stromal cell therapy Revascor Regenerative Medicine Advanced Therapy  designation. This follows the submission of results from a randomised controlled trial in children with hypoplastic left heart syndrome . HLHS is a severe congenital heart disease in which the left side of the heart does not fully develop and effective pumping of oxygenated blood by the left ventricle to the rest of the body is reduced. Mesoblast notes that without immediate surgery after birth, the prognosis is dismal with HLHS overall being responsible for 25% to 40% of all neonatal cardiac mortality. Earlier this year, FDA granted Revascor both Rare Pediatric Disease Designation  and OrphanDrug Designatio","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/12/05/what-on-earth-is-happening-with-mesoblast-shares-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7501","BK4183","BK7508","MSB.AU","BK4139","BK7067","ODD","BLA.AU","MESO"],"gpt_icon":0},{"id":"2489112427","title":"FDA Grants Revascor® (Rexlemestrocel-L) Regenerative Medicine Advanced Therapy (Rmat) Designation in Children With Congenital Heart Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2489112427","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489112427?lang=en_us&edition=fundamental","pubTime":"2024-12-05 07:32","pubTimestamp":1733355139,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241204:nTUABCZKHW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MSB.AU","BK7508","BK7067","BK7501"],"gpt_icon":0},{"id":"2489129703","title":"Mesoblast Ltd-FDA Grants Mesoblast Rmat Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=2489129703","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489129703?lang=en_us&edition=fundamental","pubTime":"2024-12-05 06:59","pubTimestamp":1733353188,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241204:nTUE1PD6XX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MSB.AU","BK7067","BK7508","BK7501"],"gpt_icon":0},{"id":"2488958509","title":"Mesoblast's Cell Therapy Shows Improved Outcomes in Heart Disease Patients in Phase 3 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2488958509","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488958509?lang=en_us&edition=fundamental","pubTime":"2024-12-03 12:04","pubTimestamp":1733198678,"startTime":"0","endTime":"0","summary":"Mesoblast's  cell therapy showed improved outcomes in heart disease patients based on data from a phase 3 trial, according to a Tuesday filing with the Australian bourse.The randomized controlled study, named DREAM-HF, showed that a single intramyocardial injection of Revascor-branded allogeneic cell therapy, rexlemestrocel-L, showed an improvement in the survival of high-risk patients with ischemic heart failure and inflammation, the filing said.Results from the trial were published in November in the peer-reviewed European Journal of Heart Failure, the filing added.The company's shares were up almost 2% in recent Tuesday trade.Price : $1.83, Change: $+0.03, Percent Change: +1.50%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4125","AUD","LU1043141123.HKD","BK7508","LU0426417589.USD","BK7501","MESO","LU2238339852.HKD","LU0345774631.USD","LU0426412945.USD","LU0994945656.USD","BK7067","BK4139","MSB.AU"],"gpt_icon":0},{"id":"2488350911","title":"Top ASX shares to buy in December 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2488350911","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488350911?lang=en_us&edition=fundamental","pubTime":"2024-12-01 01:00","pubTimestamp":1732986000,"startTime":"0","endTime":"0","summary":"'Twas the night before Christmas when all through the bourse,Australian investors were feeling quite hoarse. For the ASX rallied to a dizzying height,And the cheering rang out across many a night. But now savvy folk with more cash to invest,Worry they may have missed out on the best. Fear not, good investors, for now heed this;We challenged our writers to a test of their wits. And asked them to search the market low and high;To find you the top ASX shares to buy. So, without further ado, let's look to prove,Why buying these stocks could be a smart move!","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/12/01/top-asx-shares-to-buy-in-december-2024/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7503","XJO.AU","BK7067","BK7044","NXT.AU","XAO.AU","BK7501","BKW.AU","BK7016","BK7095","BK7508","LOV.AU","BHP.AU","BK4110","BK7507","ARR.AU","BK7043","TNE.AU","ARR","BK7128","MSB.AU","BK7511","XKO.AU"],"gpt_icon":0},{"id":"2487732984","title":"Mesoblast Limited's (ASX:MSB) 17% gain last week benefited both retail investors who own 54% as well as insiders","url":"https://stock-news.laohu8.com/highlight/detail?id=2487732984","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2487732984?lang=en_us&edition=fundamental","pubTime":"2024-11-29 05:27","pubTimestamp":1732829239,"startTime":"0","endTime":"0","summary":"Significant control over Mesoblast by retail investors implies that the general public has more power to influence management and governance-related decisions. A total of 25 investors have a majority stake in the company with 44% ownership. To get a sense of who is truly in control of Mesoblast Limited , it is important to understand the ownership structure of the business. And the group that holds the biggest piece of the pie are retail investors with 54% ownership. That is, the group stands to benefit the most if the stock rises .While retail investors were the group that reaped the most benefits after last week’s 17% price gain, insiders also received a 24% cut.Let's delve deeper into each type of owner of Mesoblast, beginning with the chart below.While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. The company management answer to the board and the latter should represent the interests of shareholders. Notably, someti","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mesoblast-limiteds-asx-msb-17-212719852.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MESO","MSB","BK4139","MSB.AU","BK4006"],"gpt_icon":1},{"id":"2486078369","title":"11 ASX All Ords shares rising faster than Nvidia over the past year","url":"https://stock-news.laohu8.com/highlight/detail?id=2486078369","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486078369?lang=en_us&edition=fundamental","pubTime":"2024-11-28 13:31","pubTimestamp":1732771878,"startTime":"0","endTime":"0","summary":"S&P/ASX All Ords Index (ASX: XAO) shares have roared 20.8% higher over the past 12 months.  That's pretty impressive, but as always, there are outliers booking gains far beyond the market average. In ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/11/28/11-asx-all-ords-shares-rising-faster-than-nvidia-over-the-past-year/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["NVDX","NVDU","LU0354030438.USD","IE00BMPRXR70.SGD","SIG.AU","NVDD","SLC.AU","NVD2.UK","NXL.AU","BK4532","IE00BYXW3230.USD","NVDY","LU0107464264.USD","LU0444973449.USD","LU0689472784.USD","MSB.AU","SNVD.UK","APX.AU","LU2237438978.USD","LU0265550946.USD","NVD3.UK","LU2360107168.USD","IE00BHPRN162.USD","NVDS","LU1623119135.USD","NVDA","2NVD.UK","3NVD.UK","IPX.AU","LU1064131342.USD","LU2417539215.USD","BK4588","LU1642822529.SGD","CU6.AU","LU0203202063.USD","LU2756315318.SGD","BK4592","LU2125909759.SGD","360.AU","NVDS.UK","ZIP.AU","OBM.AU","IE00BN29S564.USD","LU2433249047.HKD","XAO.AU","LU2430703178.SGD","CAT.AU","NVD"],"gpt_icon":1},{"id":"2486385616","title":"3 ASX 300 stocks up by more than 300% in a year","url":"https://stock-news.laohu8.com/highlight/detail?id=2486385616","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486385616?lang=en_us&edition=fundamental","pubTime":"2024-11-27 06:10","pubTimestamp":1732659057,"startTime":"0","endTime":"0","summary":"As we approach the final month of trading for another year, it's exciting to look back and see which ASX 300 stocks are on track to deliver the best share price growth this year.  TheS&P/ASX 300 Indexis currently tracking at 19.5% growth over the past 12 months.  That's obviously a great result.  But hang on to your hats as we reveal the 3 ASX 300 stocks that are up by more than 300% over the past 12 months. Triple treat: 3 ASX 300 stocks shooting the lights out  Based on data provided by S & P Global Market Intelligence, there are only 3 stocks in the ASX 300 that have recorded 300% growth or more over 12 months.  1. Zip Co Ltd This ASX 300financialstock is having an absolute screamer!","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/11/27/3-asx-300-stocks-up-by-more-than-300-in-a-year/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7508","BK7501","BK7067","BK7093","MSB.AU","ZIP.AU","XKO.AU","CU6.AU","BK7096"],"gpt_icon":0},{"id":"2483390154","title":"Up 427% this year, why today is a big day for Mesoblast shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2483390154","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483390154?lang=en_us&edition=fundamental","pubTime":"2024-11-15 10:39","pubTimestamp":1731638387,"startTime":"0","endTime":"0","summary":"It's a big day for Mesoblast Ltd  shares today. Not because shares in the clinical-stage biotechnology company are gaining again. In fact, they're headed the other direction on Friday, down 8.1% in early afternoon trade at $1.635 apiece. There's no need to break out your tiny violin for longer-term stockholders, though. As you can see on the chart below, Mesoblast shares remain up an eye-watering 427% in 2024.  Rather, today is a big day for the company because Mesoblast hosted its annual general meeting  this morning. Here's what the company's top management had to say. Mesoblast shares in focus amid AGM \"This year has seen our company make significant advances as a leading developer of innovative allogeneic cellular medicines,\" chair Jane Bell said. She noted:  [Mesoblast has] an extensive clinical-stage pipeline of therapeutic assets validated by clinical data that address serious and life-threatening inflammatory illnesses. Our key areas of focus remain cardiovascular disease, chro","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/11/15/up-427-this-year-why-today-is-a-big-day-for-mesoblast-shares/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7501","AGM.AU","BK4229","MSB.AU","BK4139","MESO","AGM","BK7067","BK4195","BK7508"],"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":8,"totalSize":166,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MSB.AU\",params:#limit:5,,,undefined,":[{"date":"2025-02-26","symbol":"MSB.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740524400000,"name":null,"time":"","dateTimestamp":1740488400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MSB.AU\",market:\"AU\",,,undefined,":[]}}